Mergers and acquisitions in the pharmaceutical industry are not only a positive for the company that has made a bid for another company, but it is also good for the industry as a whole because of increases in efficiency across the entire field.
That is the argument put forth by Bruce Booth, a partner with Atlas Venture. Taking a broad look at M&A in a Forbes article, Booth notes that the impact on the industry is profound “and should be better appreciated by those involved in policy.”
